News
GAD Drug Development Has Stalled for 16 Years. iNGENu CRO Is Building the Trial Framework to Change That.
The FDA has not approved a new generalized anxiety disorder treatment since 2009. With a high placebo effect, complex neurobiology, and a long list of failed candidates, GAD represents one of psychiatry's most persistent clinical challenges. Here is what the data shows, and how precision trial design is finally shifting the odds.
→
How CRISPR Gene Editing Is Revolutionizing Genetic Disease Treatment
Explore how CRISPR gene editing is transforming genetic disease treatment, uncovering breakthroughs, safety advances, and the future possibilities of curing inherited disorders through DNA repair.
→
How Blue Light From Screens Disrupts Your Sleep Cycle and Melatonin Production
Blue light sleep disruption can delay your sleep cycle by suppressing melatonin. Learn how screen light exposure affects circadian rhythm and ways to protect sleep.
→
